Oncology Newswire

Oncology Newswire

Comprehensive Real-Time News Feed for Oncology.

Results 1 - 20 of 33,719 in Oncology

  1. Discovery made in fight against glioblastomaRead the original story w/Photo

    1 hr ago | WPTV Local News

    ... so the group of researchers wanted to know why some patients live longer than others. Professor of Radiation Oncology, Dr. Baldassarre Stea, says the clue lies in the RNA of short and long-term patients. What they found is a gene called WIF1 is ...

    Comment?

  2. New insights into childhood cancerRead the original story w/Photo

    15 hrs ago | EurekAlert!

    ... of the article's last-named authors, Prof. Dr. Johannes Schulte, of Charite's Department of Pediatrics, Division of Oncology and Hematology, sums up the study's main findings as follows: "The data produced by our work provide us with a precise means ...

    Comment?

  3. Odey Asset Management Group Ltd Sells 125,300 Shares of Shire PLCRead the original story w/Photo

    34 min ago | IntersportsWire

    ... areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology. Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades ...

    Comment?

  4. Perjeta given green light in Scotland as early-stage breast cancer treatmentRead the original story w/Photo

    37 min ago | Sutton Guardian

    Hundreds of breast cancer patients are expected to benefit after a sought-after drug was approved for use by the NHS in Scotland in certain circumstances. The Scottish Medicines Consortium has given the green light to Perjeta as a new treatment option before surgery for patients with early-stage breast cancer.

    Comment?

  5. Breast cancer testing guidelines out of date, missing genetic screening, says studyRead the original story w/Photo

    2 hrs ago | WPMT-TV York

    The current guidelines for genetic testing of breast cancer patients limit the number of women who can get tested. Because of these restrictions, these tests miss as many patients with hereditary cancers as they find, according to a study published Monday in the Journal of Clinical Oncology.

    Comment?

  6. Researchers gain new insights into pediatric tumorsRead the original story w/Photo

    2 hrs ago | Medical News

    ... of the article's last-named authors, Prof. Dr. Johannes Schulte, of Charite's Department of Pediatrics, Division of Oncology and Hematology, sums up the study's main findings as follows: "The data produced by our work provide us with a precise means ...

    Comment?

  7. Patients With Cancer Are More At Risk Of Complications Following Heart ProcedureRead the original story w/Photo

    3 hrs ago | ECNmag

    Research led by Keele University suggests that patients with cancer who undergo a common heart procedure have worse short-term clinical outcomes compared to non-cancer patients, in the largest study undertaken to date. The study, published today in the European Heart Journal , looked at 6.6 million hospital admissions in the USA over an 11-year period, in which the admitted patient underwent a percutaneous coronary intervention procedure.

    Comment?

  8. ASM: Helmsley Center doctors see their first patientRead the original story w/Photo

    3 hrs ago | KSFY

    ... see a difference. One of the first patients already has a headstart on her treatments. Loretta Kunsman, a radiation oncology patient, has already noticed the impact on her life, being able to be close to home. "So, last week was the first time I did ...

    Comment?

  9. Zacks: Analysts Anticipate Cellectis SA (CLLS) Will Announce Earnings of -$0.24 Per ShareRead the original story w/Photo

    4 hrs ago | IntersportsWire

    ... 27.68% of the company's stock. Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The ...

    Comment?

  10. A community-based program that brings patients and pathologists togetherRead the original story w/Photo

    4 hrs ago | Kevin, M.D.

    When I was in medical school, I loved pathology. The visual learning and deep understanding of disease were attractive enough that after second year, I took an extra year before clinical rotations to work as a post-sophomore fellow, working as a resident cutting specimens and performing autopsies.

    Comment?

  11. Study shows key enzyme linked to therapy resistance in deadly lung cancerRead the original story w/Photo

    4 hrs ago | PhysOrg Weblog

    ... but resistance to treatment remains a major challenge," said Mien-Chie Hung, Ph.D., chair of Molecular and Cellular Oncology. "Our study identified PKCI as a common mediator shared by multiple methods of resistance to EGFR TKIs, and it significantly ...

    Comment?

  12. CBT & Strata Oncology Enter Development DealRead the original story w/Photo

    4 hrs ago | Contract Pharma Breaking News

    CBT Pharmaceuticals and Strata Oncology have entered into an agreement to drive patient enrollment in CBT's ongoing Phase 1/2 trial of CBT-101 in cancer patients with c-Met dysregulated malignancies including non-small cell lung cancer. Under the terms of the agreement, Strata will exclusively refer Met-amplified, Met-mutation and Met-fusion advanced cancer patients identified through the Strata Trial for enrollment consideration into CBT's clinical development program for CBT-101.

    Comment?

  13. Executive Moves at RocheRead the original story w/Photo

    4 hrs ago | Contract Pharma Breaking News

    ... Anderson joined Roche in 2006 leading the Immunology Business Unit in Genentech and then took responsibility for Oncology Sales and Marketing. In 2013, he was appointed Head of Global Product Strategy based in Basel before assuming his current role ...

    Comment?

  14. Avacta, LG Chem Announce CollaborationRead the original story w/Photo

    4 hrs ago | Contract Pharma Breaking News

    To develop and commercialize multiple AffimerA therapeutics intended for treatment of patients in the fields of inflammatory disorders and oncology Avacta Group and LG Chem Life Sciences announced a multi-target collaboration and development agreement. The agreement provides LG Chem with the exclusive rights to develop and commercialize, on a worldwide basis, multiple Affimer therapeutics intended for treatment of patients in the fields of inflammatory disorders, and oncology.

    Comment?

  15. Cancer cells distinguished by artificial intelligence-based systemRead the original story w/Photo

    5 hrs ago | Science Daily

    ... images, achieving higher accuracy than human judgment. This approach could have major benefits in the field of oncology. The system is based on a convolutional neural network, a form of artificial intelligence modeled on the human visual system. In ...

    Comment?

  16. Bioasis Appoints Dr. Deborah A. Rathjen as Executive Chair of the Board of DirectorsRead the original story w/Photo

    5 hrs ago | The Galveston County Daily News

    ... her proven track record of increasing and realizing shareholder value through partnering and her expertise in CNS, oncology clinical development and strategic planning is invaluable for Bioasis as we advance our partnering objectives for the xB 3 ...

    Comment?

  17. Brokerages Set NewLink Genetics Corp (NLNK) Target Price at $4.75Read the original story w/Photo

    5 hrs ago | Daily Political

    ... will post -1.48 earnings per share for the current year. NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. ...

    Comment?

  18. Blue Earth Diagnostics Announces U.S. Food and Drug Administration (FDA) Filing Acceptance of Supplemental New Drug Application (sNDA) for 18F-fluciclovine PET Imaging in GliomaRead the original story w/Photo

    5 hrs ago | The Galveston County Daily News

    ... results from one of the Phase 3 clinical trials supporting the sNDA submission to the FDA at the Society for Neuro-Oncology annual meeting in November 2018. The study, BED006, was a prospective, blinded image evaluation that examined the diagnostic ...

    Comment?

  19. Head to Head Review: XencorRead the original story w/Photo

    5 hrs ago | Daily Political

    ... I clinical trial for asthma and allergic diseases. Its product candidates also comprise XmAb14045, a bispecific oncology candidate, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; XmAb13676 that is in Phase I clinical ...

    Comment?

  20. Daiichi Sankyo and Sarah Cannon Research Institute Launch Strategic...Read the original story w/Photo

    6 hrs ago | The Virginian-Pilot

    Daiichi Sankyo Company, Limited and Sarah Cannon Research Institute announced today a strategic oncology development collaboration. This partnership brings together Daiichi Sankyo's expertise in developing novel cancer agents with Sarah Cannon's leadership in designing and optimizing clinical trials to expand treatment options for patients.

    Comment?